Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

DESMOPRESSIN ACETATE

All products: general benefit

DDAVP · DIN 00402516 · 0.1mg/mL · Nas Sol-2.5mL Pk

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.Discontinued 2021-01-29 · checked 2026-09-20
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
DDAVP · DIN 00402516 Manufacturer: Ferring Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2021-01-29 · brand DDAVP RHINYLE · ATC H01BA02 DESMOPRESSIN · form Solution · route Nasal · ingredients DESMOPRESSIN ACETATE 0.1 MG/ML · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

DDAVP: Formulary list price $52.0375/unit (unit not stated in source; not the patient's cost)

Ministry pays: $52.0375 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14413 · Verify on the e-Formulary ↗ (DIN 00402516)

Source record
DIN 00402516: DDAVP Raw flags: sec3=Y Item: 682800005; group id 790; item number 1921; lccId None; manufacturer id FEI Source form: Nas Sol-2.5mL Pk; strength: 0.1mg/mL Recorded listing: General benefit Source prices (unrounded): $52.0375; ministry $52.0375 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00402516 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14413
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2021-01-29 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:28 Pituitary Agents) and how they are covered

Matched class: 68:28 Pituitary Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: THYROTROPIN ALFA 68:28 Pituitary Agents

THYROTROPIN ALFA

· 1 products · General benefit · strengths: 0.9mg/mL · Inj Pd-2x1.1mg Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:28
Full class listing Related classes: 68:04 Corticosteroids, 68:08 Androgens, 68:12 Contraceptives, 68:16 Estrogens, 68:20 Anti-Diabetic Agents, 68:24 Parathyroid Agents, 68:32 Progestogens and Oral Contraceptives, 68:36 Thyroids, 68:38 Anti-Thyroids Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE DDAVP injection is indicated for prophylaxis of mild hemophilia A and mild von Willebrand’s disease Type I, and for the treatment of central diabetes insipidus. Hemophilia A DDAVP injection is indicated for patients with hemophilia A with Factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively, when administered 45 minutes prior to the scheduled procedure. DDAVP will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. In certain clinical situations, it may be justified to try DDAVP in patients with Factor VIII levels between 2-5%, however, these patients should be carefully monitored. Von Willebrand’s Disease (Type I) DDAVP injection is indicated for patients with mild to moderate classic von Willebrand’s Disease (Type I) with Factor VIII levels greater than 5%. DDAVP will often maintain hemostasis in surgical procedures and postoperatively when administered 45 minutes prior to the scheduled procedure. … https://pdf.hres.ca/dpd_pm/00044657.PDF PM date: April 5, 2017 Source product: DDAVP INJ 4MCG/ML; DIN 00873993; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.